| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1022244238 |
| P356 | DOI | 10.1038/BMT.2009.134 |
| P698 | PubMed publication ID | 19543327 |
| P5875 | ResearchGate publication ID | 26308018 |
| P50 | author | William Janssen | Q42756169 |
| P2093 | author name string | Y Huang | |
| D Sullivan | |||
| A List | |||
| L Perez | |||
| C Anasetti | |||
| M Alsina | |||
| M A Kharfan-Dabaja | |||
| J Perkins | |||
| T Field | |||
| H F Fernandez | |||
| E Ayala | |||
| J Lancet | |||
| P2860 | cites work | Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study | Q24563021 |
| Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan | Q33841438 | ||
| Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). | Q34100754 | ||
| Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. | Q34128471 | ||
| A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome | Q34308142 | ||
| Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. | Q40573634 | ||
| A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome | Q43796843 | ||
| Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease | Q44694393 | ||
| Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. | Q44836524 | ||
| Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective s | Q46727249 | ||
| Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis | Q46790735 | ||
| Comparable non-relapse mortality and survival after HLA-identical sibling blood stem cell transplantation with reduced or conventional-intensity preparative regimens for high-risk myelodysplasia or acute myeloid leukemia in first remission. | Q46914752 | ||
| Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome | Q47572808 | ||
| A Proportional Hazards Model for the Subdistribution of a Competing Risk | Q56885139 | ||
| Rituximab plus CHOP (R-CHOP) overcomes PRDM1-associated resistance to chemotherapy in patients with diffuse large B-cell lymphoma | Q80019214 | ||
| Improved outcome for peripheral blood stem cell transplantation for advanced primary myelodysplastic syndrome | Q80927071 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 255-260 | |
| P577 | publication date | 2009-06-22 | |
| P1433 | published in | Bone Marrow Transplantation | Q4941523 |
| P1476 | title | 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. | |
| P478 | volume | 45 |
| Q34960346 | 5-Azacytidine as Salvage Treatment in Relapsed Myeloid Tumors after Allogeneic Bone Marrow Transplantation |
| Q48309941 | A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. |
| Q40276791 | Allogeneic Hematopoietic Stem Cell Transplantation Is Underutilized in Older Patients with Myelodysplastic Syndromes |
| Q36431041 | Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how? |
| Q36811828 | Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: the past decade |
| Q33856972 | Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study |
| Q46373480 | Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire |
| Q36768610 | Azacitidine in the management of patients with myelodysplastic syndromes |
| Q37632391 | Azacitidine: a review of its use in higher-risk myelodysplastic syndromes/acute myeloid leukaemia |
| Q34273735 | Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia |
| Q37707098 | Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts |
| Q26827079 | Beyond hypomethylating agents failure in patients with myelodysplastic syndromes |
| Q36608689 | CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse |
| Q27022725 | Clinical Results of Hypomethylating Agents in AML Treatment |
| Q64117000 | Clinical impact of the loss of chromosome 7q on outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem cell transplantation |
| Q52901403 | Cost-effectiveness of treatments for high-risk myelodysplastic syndromes after failure of first-line hypomethylating agent therapy. |
| Q58110507 | Current Management and Recent Advances in the Treatment of Chronic Myelomonocytic Leukemia |
| Q36063049 | Current status of allogeneic hematopoietic cell transplantation for MDS. |
| Q53088109 | Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation. |
| Q91866430 | Decitabine-Containing Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Intermediate- and High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia: Potential Decrease in the Incidence of Acute Graft versus |
| Q48733699 | Dynamic prognostic value of the revised international prognostic scoring system following pretransplant hypomethylating treatment in myelodysplastic syndrome |
| Q36890784 | Early hematopoietic stem cell transplant is associated with favorable outcomes in children with MDS. |
| Q24608659 | Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine |
| Q33863567 | Epigenetic therapies in MDS and AML |
| Q38112417 | Epigenetic therapy in allogeneic hematopoietic stem cell transplantation |
| Q53429887 | Feasibility of hypomethylating agents followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome. |
| Q101574287 | Gene expression signatures associated with sensitivity to azacitidine in myelodysplastic syndromes |
| Q38252578 | Hematopoietic Cell Transplantation for Older Patients with MDS. |
| Q37738524 | High-risk myelodysplastic syndromes: chemotherapy, transplantation, and beyond |
| Q37169115 | Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). |
| Q41359251 | Impact of prior azacitidine on the outcome of allogeneic hematopoietic transplantation for myelodysplastic syndrome |
| Q30884173 | Interpreting outcome data in hematopoietic cell transplantation for leukemia: tackling common biases. |
| Q34217884 | Multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome: Blood |
| Q87476851 | Multicenter study evaluating the impact of hypomethylating agents as bridging therapy to hematopoietic stem cell transplantation in myelodysplastic syndromes |
| Q35605318 | NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic ma |
| Q34044024 | NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Tr |
| Q26829132 | New ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndrome |
| Q38540859 | Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents |
| Q90209225 | Pre-transplant hypomethylating agents do not influence post-transplant survival in myelodysplastic syndrome |
| Q36036263 | Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. |
| Q39527812 | Response to pretransplant hypomethylating agents influences the outcome of allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndromes |
| Q36920394 | Review of stem-cell transplantation for myelodysplastic syndromes in older patients in the context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome emanating from the Centers for Medicare and M |
| Q34549306 | Role and timing of hematopoietic cell transplantation for myelodysplastic syndrome |
| Q43272245 | Successful treatment of molecular relapse in NPM1-positive AML using 5-azacytidine |
| Q88472148 | TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome |
| Q52897534 | The bridge treatment selected at the decision for transplantation did not affect the outcomes in patients with MDS. |
| Q38160051 | The role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm |
| Q35854094 | Transplantation for myelodysplastic syndrome in the era of hypomethylating agents |
| Q41809427 | Treatment of acute erythroleukemia with Azacitidine: A case series |
| Q38176519 | Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT). |
| Q38235662 | Update on the pharmacotherapy for myelodysplastic syndromes. |
| Q24605618 | Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations |
| Q38132814 | When is the optimal timing for allogeneic transplantation in the case of MDS patients treated with hypomethylating agents? |
| Q89257275 | [Advances in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes] |
Warning: Trying to access array offset on value of type null in /home/httpd/vhosts/renenyffenegger.ch/opendata.renenyffenegger.ch/Wikimedia/Wikidata/entity/main.php on line 1120 Warning: Trying to access array offset on value of type null in /home/httpd/vhosts/renenyffenegger.ch/opendata.renenyffenegger.ch/Wikimedia/Wikidata/entity/main.php on line 1120
Search more.